Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.68, $0.12 better than the analyst estimate of $0.56. Revenue for the quarter came in at $3.8 billion versus the consensus estimate of $3.78 billion.

GUIDANCE:

Teva Pharma sees FY2022 EPS of $2.40-$2.60. Teva Pharma sees FY2022 revenue of $15-15.6 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.